ARTICLE | Deals
Buyout of F-star builds pipeline of Sino Biopharm’s invoX unit
Building international business through overseas subsidiary, Chinese company buys U.K. biotech with tetravalent bispecifics, STING agonist
June 23, 2022 3:58 PM UTC
A Sino Biopharm subsidiary’s acquisition of F-star represents the Chinese company’s latest step in its overseas strategy, adding a pipeline of tetravalent bispecifics and a STING program.
The $161 million cash takeout by invoX Pharma Ltd. will end the 16-year history of F-star Therapeutics Inc. (NASDAQ:FSTX) as an independent company. Sino Biopharmaceutical Ltd. (HKEX:1177) established invoX as a U.K.-based international subsidiary last year to expand its business outside of China...